No revenue - actualy they do.
No product - Actualy they have rather alot of diversifying products.
No deals -Biosite, IDEXX, regen + all the other acca' tie ups
No management (worth speaking of) - ok , why dii sandra steiner leave? A very valid point which will no doubt come to light soon.
No cash ( ditto ) - they have cash for about another 8 months if you look properly.
No investor confidence ( ditto )- ok, but that makes for a good buy opo'.
Where do you think I am wrong - and why? virtualy in every piont that you make.